Sugi Predict

Sugi Predict / Targets / BMX

BMX

Cytoplasmic tyrosine-protein kinase BMX · P51813 · BMX on Sugi Atlas →

50,281 patent compounds predicted against BMX, 39,483 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL123348 SCHEMBL123348 1.00 3/20
SCHEMBL123351 SCHEMBL123351 0.81 3/20
SCHEMBL123062 SCHEMBL123062 0.81 3/20
SCHEMBL124479 SCHEMBL124479 0.79 3/20
SCHEMBL123779 SCHEMBL123779 0.78 3/20
SCHEMBL148535 SCHEMBL148535 0.76 3/20
SCHEMBL122287 SCHEMBL122287 0.75 3/20
SCHEMBL123582 SCHEMBL123582 0.75 3/20
SCHEMBL147980 SCHEMBL147980 0.75 3/20
SCHEMBL124380 SCHEMBL124380 0.72 3/20
SCHEMBL122291 SCHEMBL122291 0.71 3/20
SCHEMBL124379 SCHEMBL124379 0.70 3/20
SCHEMBL122276 SCHEMBL122276 0.70 3/20
SCHEMBL122294 SCHEMBL122294 0.70 3/20
SCHEMBL123818 SCHEMBL123818 0.69 3/20
SCHEMBL147342 SCHEMBL147342 0.68 3/20
SCHEMBL123462 SCHEMBL123462 0.58 3/20
SCHEMBL93510 SCHEMBL93510 1.00 2/20
SCHEMBL93699 SCHEMBL93699 1.00 2/20
SCHEMBL123056 SCHEMBL123056 1.00 2/20

Clinical trials — most relevant to BMX by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Effect of the Preoperative Oral Carbohydrate Attenuating Immediate Postoperative Insulin Resistance on PI3K Dependent Signaling Pathway PHASE4COMPLETED
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy PHASE2COMPLETED
Study in Adult Ph-positive ALL PHASE2UNKNOWN
Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib PHASE1/PHASE2RECRUITING
BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer PHASE1/PHASE2NOT_YET_RECRUITING
Trial of BMX-001 or Placebo in Head and Neck Cancer Patients PHASE2WITHDRAWN
Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma PHASE1/PHASE2COMPLETED
Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma PHASE2COMPLETED
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma PHASE2COMPLETED
Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma PHASE2COMPLETED
Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission PHASE2NOT_YET_RECRUITING
Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer PHASE1/PHASE2COMPLETED
Improving Treatment Outcomes in Chronic Myeloid Leukaemia Patients Using Imatinib and Artesunate Combination Therapy PHASE2ACTIVE_NOT_RECRUITING
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia PHASE1RECRUITING
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 PHASE1COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 PHASE1WITHDRAWN
Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma PHASE1COMPLETED
Nilotinib in Huntington's Disease PHASE1UNKNOWN
FAK Inhibitor in Patients With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients PHASE1COMPLETED
Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia PHASE1RECRUITING
Itacitinib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab) PHASE1COMPLETED
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia nanUNKNOWN
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA nanRECRUITING
K-RAS Oncogene Mutation in Patients With Advanced Non-Small Cell Lung Cancer Associated With Exposure to Wood Smoke and Tobacco Smoking: Therapeutic Implications nanCOMPLETED
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients nanCOMPLETED
Expression of CD19 Complex in Lymphoproliferative Disorders nanUNKNOWN
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a BMX binder may also engage these)

ProteinNameSimilarity
P97504 — 0.999 P97504 →
P35991 — 0.998 P35991 →
TXK Tyrosine-protein kinase TXK 0.998 landscape →
Q64725 — 0.995 Q64725 →
Q60629 — 0.993 Q60629 →
BTK Tyrosine-protein kinase BTK 0.993 landscape →
Q00655 — 0.993 Q00655 →
O13147 — 0.992 O13147 →
P70600 — 0.992 P70600 →
P48025 — 0.992 P48025 →
SYK Tyrosine-protein kinase SYK 0.992 landscape →
P43404 — 0.991 P43404 →
P42682 — 0.991 P42682 →
Q54Y55 — 0.991 Q54Y55 →
DCLK1 Serine/threonine-protein kinase DCLK1 0.990 landscape →
Q54RB7 — 0.990 Q54RB7 →
O12990 — 0.989 O12990 →
ITK Tyrosine-protein kinase ITK/TSK 0.989 landscape →
Q8JH64 — 0.989 Q8JH64 →
Q62689 — 0.989 Q62689 →
F1N9Y5 — 0.989 F1N9Y5 →
P52332 — 0.988 P52332 →
Q8AXB4 — 0.988 Q8AXB4 →
P08630 — 0.988 P08630 →
P10686 — 0.988 P10686 →
JAK2 Tyrosine-protein kinase JAK2 0.988 landscape →
ZAP70 Tyrosine-protein kinase ZAP-70 0.988 landscape →
P54757 — 0.987 P54757 →
Q07407 — 0.987 Q07407 →
Q17850 — 0.987 Q17850 →